Due to the rising number of product launches, which is anticipated to fuel market expansion over the course of the forecast period. For instance, in 2015, the Spine and Trauma & Extremities Divisions of Stryker Corporation introduced BIO4, a novel therapeutic option to autograft for foot and ankle surgery that does not require secondary surgical sites for the harvesting of autograft tissue.
Artificial bones are typically used to replace damaged or missing bone tissue, whether due to injury or disease. Traditional bone grafts involve taking bone tissue from another part of the patient's body, which can be both painful and invasive. In contrast, artificial bones can be designed to fit the specific needs of each patient, providing a more personalized approach to treatment.
Another advantage of artificial bones is their ability to be customized. With traditional bone grafts, the size and shape of the graft are limited by the amount of bone tissue available from the patient's body. With artificial bones, however, the size and shape can be precisely tailored to fit the patient's needs, resulting in a more effective treatment.
Due to an increase in product launches, the ceramics segment of the material market is anticipated to lead Artificial Bone Market growth.
Medtronic Plc., Johnson & Johnson, Baxter International Inc., Smith & Nephew plc, Stryker Corporation, NuVasive, Inc., Allosource, Curasan, Inc., Ziacom Medical SLU, Orthofix International N.V., Biomatlante, and DSM are significant players in the global single-use products in the biopharmaceutical market.
Read More:
https://knackersblogger.blogspot.com/2023/02/artificial-bone-market-size-share.html
